ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
BeiGene has a strong presence at this year’s AACR, which features several notable duels.
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.
The 2024 AACR abstract title drop features several noteworthy clinical studies.